Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy
In this Rapid Readout, Dr Paul Hahn shares his presentation from the 2023 ASRS annual meeting. This study compares the efficacy of the two FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of the phase 3 trials.
EP. 1: Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy
September 8th 2023A retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.
